Cysteinyl Leukotriene Receptor Antagonism by Montelukast to Treat Visual Deficits
ATM Seetharaman, CE Owens… - Journal of Ocular …, 2024 - liebertpub.com
Montelukast, a Food and Drug Administration-approved drug for asthma and allergic rhinitis
modulates leukotriene (LT) receptors and serves as a critical anti-inflammatory agent …
modulates leukotriene (LT) receptors and serves as a critical anti-inflammatory agent …
[HTML][HTML] Distribution of the cysteinyl leukotriene system components in the human, rat and mouse eye
SM Brunner, F Schrödl, J Preishuber-Pflügl… - Experimental Eye …, 2023 - Elsevier
The cysteinyl leukotrienes (CysLTs) have important functions in the regulation of
inflammation and cellular stress. Blocking the CysLT receptors (CysLTRs) with specific …
inflammation and cellular stress. Blocking the CysLT receptors (CysLTRs) with specific …
Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double …
E El-Khateeb, EI El-Berri, EM Mosalam… - Frontiers in …, 2023 - frontiersin.org
Background: Type 2 diabetes mellitus (T2DM) is common with obesity. Metformin is a first-
line therapy for this condition. However, it has only a minor impact on weight loss in some …
line therapy for this condition. However, it has only a minor impact on weight loss in some …
Evaluation of Effect of Montelukast in the Model of Streptozotocin Induced Diabetic Nephropathy in Rats
D Kokate, P Marathe - Indian Journal of Endocrinology and …, 2024 - journals.lww.com
Background: Diabetic nephropathy is a progressive condition and a leading cause of end-
stage renal disease. Oxidative stress and inflammation play an important role in its …
stage renal disease. Oxidative stress and inflammation play an important role in its …
[HTML][HTML] Cysteine Leukotriene Receptor Antagonist-Montelukast Effects on Diabetic Retinal Microvascular Endothelial Cells Curtail Autophagy
AM Awad, ATM Seetharaman… - … & Visual Science, 2024 - tvst.arvojournals.org
Purpose: Diabetic macular edema (DME) is the primary cause of vision impairment in
diabetic retinopathy (DR) patients. A previous study has shown the efficacy of montelukast, a …
diabetic retinopathy (DR) patients. A previous study has shown the efficacy of montelukast, a …
Discovery and Development of the Quininib Series of Ocular Drugs
N Mahon, K Slater, J O'Brien, Y Alvarez… - Journal of Ocular …, 2022 - liebertpub.com
The quininib series is a novel collection of small-molecule drugs with antiangiogenic,
antivascular permeability, anti-inflammatory, and antiproliferative activity. Quininib was …
antivascular permeability, anti-inflammatory, and antiproliferative activity. Quininib was …